Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)

v3.25.1
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)
12 Months Ended
Dec. 31, 2024
Prepaid Expenses And Other Current Assets  
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS

The Company’s prepaid expenses and other current assets consist of the following:

 

    December 31, 2024     December 31, 2023  
Other receivables   £ 7,837     £ 51,584  
VAT owed to the Company     80,411       135,642  
Prepaid clinical trial costs     307,519       307,519  
Deferred clinical trial testing costs     1,177,500       1,177,500  
Deferred investor relations activity costs     1,523,206       -  
Deferred collaboration agreement costs     331,283       -  
Other prepayments     479,284       522,480  
Total prepaid expenses and other current assets   £ 3,907,040     £ 2,194,725